Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439â444 (2007).
Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251â2259 (2017).
Kalinsky, K. et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor. JAMA Oncol. 7, 271 (2021).
Kalinsky, K. et al. Ipatasertib in patients with tumors with AKT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) sub-protocol Z1K. Eur. J. Cancer 174, S8âS9 (2022).
Smyth, L. M. et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 E17K-mutant, ER-positive metastatic breast cancer. Clin. Cancer Res. 26, 3947â3957 (2020).
Banerji, U. et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin. Cancer Res. 24, 2050â2059 (2018).
Truebestein, L. et al. Structure of autoinhibited Akt1 reveals mechanism of PIP3-mediated activation. Proc. Natl Acad. Sci. USA 118, e2101496118 (2021).
LuÄiÄ, I. et al. Conformational sampling of membranes by Akt controls its activation and inactivation. Proc. Natl Acad. Sci. USA 115, E3940âE3949 (2018).
Hoxhaj, G. & Manning, B. D. The PI3KâAKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74â88 (2020).
Landgraf, K. E., Pilling, C. & Falke, J. J. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47, 12260â12269 (2008).
Bae, H. et al. PH domain-mediated autoinhibition and oncogenic activation of Akt. eLife 11, e80148 (2022).
Rudolph, M. et al. AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer 16, 622 (2016).
Cohen, Y. et al. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol. Oncol. 116, 88â91 (2010).
Yesilöz, Ã. et al. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro. Oncol. 19, 1088â1096 (2017).
Clark, V. E. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077â1080 (2013).
Varkaris, A. et al. Allosteric PI3Kα inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-23-0704 (2023).
Lindhurst, M. J. et al. Ubiquitous expression of Akt1 p.(E17K) results in vascular defects and embryonic lethality in mice. Hum. Mol. Genet. 29, 3350â3360 (2020).
Lindhurst, M. J. et al. A mosaic activating mutation in AKT1 associated with the proteus syndrome. N. Engl. J. Med. 365, 611 (2011).
Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058â2070 (2023).
Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728â1731 (2001).
Dummler, B. et al. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 26, 8042â8051 (2006).
George, S. et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304, 1325â1328 (2004).
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349â38352 (2001).
Buzzi, F. et al. Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass. Mol. Cell. Biol. 30, 601â612 (2010).
Chen, W. S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes Dev. 15, 2203â2208 (2001).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548â551 (2013).
Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371â2381 (2021).
Jänne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120â131 (2022).
Lapierre, J. M. et al. Discovery of 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor. J. Med. Chem. 59, 6455â6469 (2016).
Yu, Y. et al. Targeting AKT1-E17K and the PI3K/AKT pathway with an allosteric AKT inhibitor, ARQ 092. PLoS ONE 10, e0140479 (2015).
Molina, D. M. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84â87 (2013).
Parker, C. G. & Pratt, M. R. Click chemistry in proteomic investigations. Cell 180, 605â632 (2020).
Haffner, M. C. et al. Phenotypic characterization of two novel cell line models of castrationâresistant prostate cancer. Prostate 81, 1159â1171 (2021).
Sangai, T. et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin. Cancer Res. 18, 5816â5828 (2012).
Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P. & Vogt, P. K. The Akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA 95, 14950â14955 (1998).
Kovacina, K. S. et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278, 10189â10194 (2003).
Oshiro, N. et al. The proline-rich Akt substrate of 40âkDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 282, 20329â20339 (2007).
Vasta, J. D. et al. Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement. Cell Chem. Biol. 25, 206â214 (2018).
Tamames, B., Sousa, S. F., Tamames, J., Fernandes, P. A. & Ramos, M. J. Analysis of zinc-ligand bond lengths in metalloproteins: trends and patterns. Proteins 69, 466â475 (2007).
Leussing, D. L. & Leach, B. E. Stabilities, rates of formation, and rates of transimination in aqueous solutions of some zinc(II)-Schiff base complexes derived from salicylaldehyde. J. Am. Chem. Soc. 93, 3377â3384 (1971).
Laitaoja, M., Valjakka, J. & Jänis, J. Zinc coordination spheres in protein structures. Inorg. Chem. 52, 10983â10991 (2013).
Bruyneel, W., Charette, J. J. & De Hoffmann, E. Kinetics of hydrolysis of hydroxy and methoxy derivatives of N-benzylidene-2-aminopropane. J. Am. Chem. Soc. 88, 3808â3813 (1966).
Arslan, P., Di Virgilio, F., Beltrame, M., Tsien, R. Y. & Pozzan, T. Cytosolic Ca2+ homeostasis in Ehrlich and Yoshida carcinomas. A new, membrane-permeant chelator of heavy metals reveals that these ascites tumor cell lines have normal cytosolic free Ca2+. J. Biol. Chem. 260, 2719â2727 (1985).
Cuesta, A. & Taunton, J. Lysine-targeted inhibitors and chemoproteomic probes. Annu. Rev. Biochem. 88, 365â381 (2019).
Yang, T. et al. Reversible lysine-targeted probes reveal residence time-based kinase selectivity. Nat. Chem. Biol. 18, 934â941 (2022).
Katz, B. A. et al. Design of potent selective zinc-mediated serine protease inhibitors. Nature 391, 608â612 (1998).
Liu, W. et al. Lactate regulates cell cycle by remodelling the anaphase promoting complex. Nature 616, 790â797 (2023).
Oksenberg, D. et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br. J. Haematol. 175, 141â153 (2016).
Vichinsky, E. et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N. Engl. J. Med. 381, 509â519 (2019).
Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometryâbased proteomics. Nat. Methods 14, 513â520 (2017).
Yu, F., Haynes, S. E. & Nesvizhskii, A. I. IonQuant enables accurate and sensitive label-free quantification with FDR-controlled match-between-runs. Mol. Cell. Proteomics 20, 100077 (2021).
Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343â345 (2009).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367â1372 (2008).
Davies, B. R. et al. Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. Mol. Cancer Ther. 14, 2441â2451 (2015).
Kabsch, W. XDS. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66, 125â132 (2010).
Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. Sect. D: Biol. Crystallogr. 69, 1204â1214 (2013).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658â674 (2007).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66, 486â501 (2010).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66, 213â221 (2010).
Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 43, 186â190 (2010).
